Peripheral Arterial Disease Clinical Trial
Official title:
Clinical Trial of The ShOckwave Medical Peripheral Lithoplasty® System Used to Treat Moderate and Severely CalcIfied FemOropopliteal Arteries in ChiNese Patients (SOLUTION Trial)
Verified date | June 2022 |
Source | Genesis Medtech Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a prospective, multicenter, single arm study, to support the safety and effectiveness assessment of the Shockwave Medical Peripheral IVL System applied to Chinese patients
Status | Active, not recruiting |
Enrollment | 20 |
Est. completion date | July 30, 2023 |
Est. primary completion date | January 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: General 1. Subject or subject's legal representative have been informed of the nature of the study, agrees to participate and has signed the approved consent form. 2. Age of subject is > 18 and =80, male or female. 3. Rutherford Category 2 to 5 of the target limb (If both limbs are eligible for the study, one limb will be selected as the target limb at the discretion of the investigator) 4. Estimated life expectancy >1 year. 5. Subject is a suitable candidate for angiography and endovascular intervention in the opinion of the investigator or per hospital guideline. 6. Subject is intended to undergo treatment with IVL followed by DCB. Angiographic 7. Target lesion that is located in a native, de novo superficial femoral artery (SFA) or popliteal artery 8. Target lesion reference vessel diameter is between 4.0mm and 7.0mm by visual estimate. 9. Target lesion is =70% stenosis by investigator via visual estimate. 10. Target lesion length is =180mm for lesions 70-99% stenosed. Target lesion can be all or part of the 180mm treated zone. 11. Chronic total occlusion (CTO), lesion length is =100mm of the total =180mm target lesion. 12. Subject has at least one patent tibial vessel on the target leg with runoff to the foot, defined as no stenosis >50%. 13. Calcification is at least moderate defined as presence of fluoroscopic evidence of calcification: 1) on parallel sides of the vessel and 2) extending > 50% the length of the lesion if lesion is =50mm in length; or extending for minimum of 20mm if lesion is <50mm in length. Exclusion Criteria: General 1. Subject has active infection requiring antibiotic therapy. 2. Planned target limb major amputation (above the ankle). 3. History of prior endovascular or surgical procedure on the index limb within the past 30 days or planned within 30 days of the index procedure. 4. Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter. 5. Subject in whom antiplatelet or anticoagulant therapy is contraindicated. 6. Subject has known allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated. 7. Subject has known allergy to urethane, nylon, or silicone. 8. Myocardial infarction within 60 days prior to enrollment. 9. History of stroke within 60 days prior to enrollment. 10. History of thrombolytic therapy within two weeks of enrollment. 11. Serum creatinine greater than 2 times the upper reference limit 12. Subject is pregnant or nursing. 13. Women of childbearing potential (18 years to less than 2 years post-menopausal and not surgically sterile) with positive blood or urine pregnancy test at screening 14. Subject is participating in another research study that has not reached the primary endpoint. 15. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post- treatment. 16. The use of specialty balloons (Scoring or cutting balloon), re-entry or atherectomy devices. Angiographic 17. In-stent restenosis within 10mm of the target zone. 18. Lesions within 10mm of the ostium of the SFA or within 10mm of the ostium of the anterior tibial artery. 19. Evidence of aneurysm or thrombus in target vessel. 20. No calcium or mild calcium in the target lesion. 21. Target lesion within native or synthetic vessel grafts. 22. Subject has significant non-target lesion (>50% stenosis or occlusion) within target limb (e.g. iliac or common femoral) not successfully treated prior to treatment of the target lesion. 23. Subject requires treatment of a peripheral lesion on the ipsilateral limb distal to target site at the time of the index procedure. 24. Failure to successfully cross the guidewire across the target lesion; successful crossing defined as tip of the guidewire distal to the target lesion in the absence of flow limiting dissections or perforations. |
Country | Name | City | State |
---|---|---|---|
China | Affilated Hanzhou First People's Hospital, Zhejiang University School of Medicine | Shanghai | |
China | Huashan Hospital | Shanghai | |
China | Shanghai Jiaotong university school of medicine,Renji Hospital | Shanghai | |
China | Shanghai Jiaotong University School of Medicine,The Ninth People's Hospital | Shanghai | |
China | Zhongshan Hospital | Shanghai |
Lead Sponsor | Collaborator |
---|---|
Genesis Medtech Corporation |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Procedural success | defined as residual stenosis =30% without flow-limiting dissection (= grade D) post IVL treatment (prior to DCB)by angiographic core lab | Immediately post index procedure | |
Primary | Major Adverse Event (MAE) at 30 days | defined as:
Need for emergency surgical revascularization of target limb Unplanned target limb major amputation (above the ankle) Symptomatic thrombus or distal emboli that require surgical, mechanical or pharmacologic means to improve flow and extend hospitalization Perforations that require an intervention, including bail-out stenting |
30 days post index procedure |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06032065 -
Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD)
|
Phase 3 | |
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03506633 -
Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
|
N/A | |
Active, not recruiting |
NCT03506646 -
Dietary Nitrate Supplementation and Thermoregulation
|
N/A | |
Active, not recruiting |
NCT04677725 -
NEtwork to Control ATherothrombosis (NEAT Registry)
|
||
Recruiting |
NCT05961943 -
RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients
|
N/A | |
Recruiting |
NCT06047002 -
Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
|
||
Completed |
NCT03185052 -
Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach
|
N/A | |
Recruiting |
NCT05992896 -
A Study of Loco-Regional Liposomal Bupivacaine Injection
|
Phase 4 | |
Completed |
NCT04635501 -
AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial
|
N/A | |
Recruiting |
NCT04584632 -
The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery
|
N/A | |
Withdrawn |
NCT03994185 -
The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease
|
N/A | |
Withdrawn |
NCT03538392 -
Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
|
||
Recruiting |
NCT02915796 -
Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty
|
Phase 1 | |
Active, not recruiting |
NCT02900924 -
Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
|
||
Completed |
NCT02901847 -
To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities.
|
N/A | |
Not yet recruiting |
NCT02387450 -
Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT02455726 -
Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease
|
N/A | |
Withdrawn |
NCT02126540 -
Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries
|
N/A | |
Completed |
NCT02022423 -
Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease
|
N/A |